Sign In
Buy SCPH
$5.67
+0 (+0%)
At Close: Jan 06, 2026
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
06:15pm, Wednesday, 14'th May 2025
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.36 per share a year ago.
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 14'th May 2025
Generated net FUROSCIX ® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track fo
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
04:01pm, Wednesday, 07'th May 2025
Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
04:01pm, Thursday, 01'st May 2025
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pati
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
07:13pm, Wednesday, 19'th Mar 2025
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Par
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates
06:10pm, Wednesday, 19'th Mar 2025
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.35 per share a year ago.
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:01pm, Wednesday, 19'th Mar 2025
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
04:01pm, Wednesday, 12'th Mar 2025
Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Wednesday, 05'th Mar 2025
ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
04:01pm, Wednesday, 26'th Feb 2025
BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:01pm, Wednesday, 05'th Feb 2025
BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
08:00am, Friday, 10'th Jan 2025
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range
scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript
07:05pm, Wednesday, 13'th Nov 2024
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve
ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates
06:20pm, Wednesday, 13'th Nov 2024
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.41 per share a year ago.
